eFFECTOR Therapeutics Inc. [NASDAQ: EFTR] closed the trading session at $0.65 on 08/09/22. The day’s price range saw the stock hit a low of $0.6011, while the highest price level was $1.99. The company report on August 9, 2022 that eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial.
The stocks have a year to date performance of -92.13 percent and weekly performance of -16.96 percent. The stock has been moved at -87.29 percent over the last six months. The stock has performed -53.76 percent around the most recent 30 days and changed -73.92 percent over the most recent 3-months.
If compared to the average trading volume of 83.31K shares, EFTR reached to a volume of 57725643 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about eFFECTOR Therapeutics Inc. [EFTR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EFTR shares is $18.68 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EFTR stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for eFFECTOR Therapeutics Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on January 25, 2022. The new note on the price target was released on November 09, 2021, representing the official price target for eFFECTOR Therapeutics Inc. stock. Previously, the target price had yet another raise to $20, while Credit Suisse analysts kept a Outperform rating on EFTR stock.
The Average True Range (ATR) for eFFECTOR Therapeutics Inc. is set at 0.19, with the Price to Sales ratio for EFTR stock in the period of the last 12 months amounting to 19.12. The Price to Book ratio for the last quarter was 1.05, with the Price to Cash per share for the same quarter was set at 1.11.
EFTR stock trade performance evaluation
eFFECTOR Therapeutics Inc. [EFTR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.96. With this latest performance, EFTR shares dropped by -53.76% in over the last four-week period, additionally sinking by -87.29% over the last 6 months – not to mention a drop of -93.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EFTR stock in for the last two-week period is set at 25.26, with the RSI for the last a single of trading hit 24.17, and the three-weeks RSI is set at 26.99 for eFFECTOR Therapeutics Inc. [EFTR]. The present Moving Average for the last 50 days of trading for this stock 1.2914, while it was recorded at 0.7973 for the last single week of trading, and 4.6207 for the last 200 days.
eFFECTOR Therapeutics Inc. [EFTR]: An insightful look at the core fundamentals
eFFECTOR Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 18.40 and a Current Ratio set at 18.40.
eFFECTOR Therapeutics Inc. [EFTR]: Insider Ownership positions
There are presently around $15 million, or 74.40% of EFTR stock, in the hands of institutional investors. The top three institutional holders of EFTR stocks are: SR ONE CAPITAL MANAGEMENT, LP with ownership of 6,822,114, which is approximately 0% of the company’s market cap and around 0.70% of the total institutional ownership; ABINGWORTH LLP, holding 4,822,114 shares of the stock with an approximate value of $3.14 million in EFTR stocks shares; and COLUMN GROUP LLC, currently with $2.81 million in EFTR stock with ownership of nearly 0% of the company’s market capitalization.
Positions in eFFECTOR Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 10 institutional holders increased their position in eFFECTOR Therapeutics Inc. [NASDAQ:EFTR] by around 1,090,800 shares. Additionally, 6 investors decreased positions by around 51,373 shares, while 7 investors held positions by with 21,976,768 shares. The mentioned changes placed institutional holdings at 23,118,941 shares, according to the latest SEC report filing. EFTR stock had 4 new institutional investments in for a total of 62,808 shares, while 2 institutional investors sold positions of 14,902 shares during the same period.